green leaves in close up photography

Epilepsy management with medicinal marijuana and cannabis

In effectively managing epilepsy, doctors appear to favor a few specific epilepsy medications, rather than all of them. These medications are well known to have lots of benefits to epileptic patients, including the ability to reduce the number of seizures, avoid temporary unconsciousness, reduce the frequency of epileptic attacks, and reduce the impact of the condition on the patient’s everyday life.

The charge mode lashes a confusing broad brush against the idea that medicinal cannabis helps patients. This theory is difficult to understand, and is based on the idea that cannabis has some sort of effect, whether it’s the same as a medication, or something else. The model couches in a narrow way, does not generally address the personalities and specific conditions of the patients, and leaves many questions unanswered, especially for a layperson. For example, what does it mean to have a 50% chance of getting another seizure, or a seizures have you permanently lose abilities? Are these chances in the range of 20% to 80%? Lots of people with recurring seizures would be ” responders.” While chances of 25% to 75% is certainly feasible, it’s not easy to imagine that the same could be expected for chronic epilepsy, with periods of illness over a decade-long duration.

To get a grasp of what kind of progress is being made, monitoring of the joints can be used to indicate progress. Joints can be checked, at intervals of every two weeks, to monitor both grams of tetrahydrocannabinol and its potency. This is known as the CBR method, where the patient is given a series of checks each month, typically about once every six months. These annual exams provide key data that can help doctors gauge the effectiveness of treatment and can help us, with more precision, design more effective medications.

green leaves in close up photography

The Focus Patient Portals

Also in 2005, a new approach to medication management was introduced in the form of the Focus Parent Portals. These portals allow for continuous medication monitoring for sites that have typically been identified as being ‘action points’ in the course of a seizure. These sites are typically the areas where brain wave patterns start to abnormally deviate from healthy brain wave patterns. A clinical team is there to intervene as soon as a deviation is noticed, resulting in a protocol change to effectively reduce or completely put an end to the event.

FocusPortal is areated drug-free alternative that is non-invasive, non-surgical, and completely safe. The first FocusPortal clinical trials took place in reputable hospitals across Europe. Now in 2006, the product is available for sale, and further FocusPortal clinical trials are in the works.

Again, what can be expected to occur is an average of 15 patients per practice opening every week. The system is being piloted in stages across several sites first; initially, the product is being tested on the sickest 25 – 30 patients. The product will then be trialed on the strongest 2 – 5 patients. From these 25, a variety of supports will be available for use. The clinical trials being developed will be done in buddy-working relationships, with the hope that using the system may help identify additional, positive, partners.